Glaucoma - Pipeline Insight, 2024

Glaucoma - Pipeline Insight, 2024

DelveInsight’s, “Glaucoma Disease- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Glaucoma Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Glaucoma Disease: Understanding

Glaucoma Disease: Overview

Glaucoma is a group of eye conditions that damage the optic nerve. The optic nerve sends visual information from eye to the brain and is vital for good vision. Damage to the optic nerve is often related to high pressure in your eye. But glaucoma can happen even with normal eye pressure. Glaucoma can occur at any age but is more common in older adults. It is one of the leading causes of blindness for people over the age of 60.

Many forms of glaucoma have no warning signs. The effect is so gradual that you may not notice a change in vision until the condition is in its later stages.

It's important to have regular eye exams that include measurements of your eye pressure. If glaucoma is recognized early, vision loss can be slowed or prevented. If you have glaucoma, you'll need treatment or monitoring for the rest of your life.

Based on the type of Glucoma, the symptoms are different. For open-angle glaucoma there are no symptoms in early stages, gradually, patchy blind spots appear on side/ Peripheral vision and in later stages, there is difficulty seeing things in central vision.

Glaucoma develops when the optic nerve becomes damaged. As this nerve gradually deteriorates, blind spots develop in your vision. For reasons that doctors don't fully understand, this nerve damage is usually related to increased pressure in the eye.

Glaucoma is basically treated with the help of medications and surgery. Several medicines designed to reduce IOP are available. These medicines are available in the form of eye drops or pills, but the drops are more common. If a blocked or slow channel is causing increased IOP, the doctor may suggest surgery to make a drainage path for fluid or destroy tissues that are responsible for the increased fluid.

Treatment for angle-closure glaucoma is different. This type of glaucoma is a medical emergency and requires immediate treatment to reduce eye pressure as quickly as possible. Medicines are usually attempted first, to reverse the angle closure, but this may be unsuccessful. A laser procedure called laser peripheral iridotomy may also be performed. This procedure creates small holes in the iris to allow for increased fluid movement.

""Glaucoma Disease- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glaucoma Disease pipeline landscape is provided which includes the disease overview and Glaucoma Disease treatment guidelines. The assessment part of the report embraces, in depth Glaucoma Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glaucoma Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Glaucoma Disease R&D. The therapies under development are focused on novel approaches to treat/improve Glaucoma Disease.

Glaucoma Disease Emerging Drugs Chapters

This segment of the Glaucoma Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glaucoma Disease Emerging Drugs

• GmbH NCX 470: Nicox Ophthalmics

NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog that is currently being developed by Nicox Ophthalmics. NCX-470 may assist glaucoma patients by a mechanism other than IOP lowering, notably by enhancing ocular perfusion. IOP reduction is the most common treatment for glaucoma, and preliminary studies suggest that if approved, NCX-470's dual mechanistic approach (nitric oxide donation and prostaglandin F2 activity) could make it the most effective single-agent glaucoma medicine in terms of IOP-lowering efficacy. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.

• DE-126: Santen Pharmaceuticals

DE-126 (ONO-9054) is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). As it has been reported that both receptors have an effect in reducing intraocular pressure, ONO-9054 is expected to give a new therapeutic options for the treatment of glaucoma. It is likely to show a superior IOP lowering effect compared to FP receptor agonists. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.

• POLAT 001: Peregrine Ophthalmic

POLAT-001 is a sustained released product of latanoprost for the medical treatment of glaucoma. The drug is a 100 nm-long nanoliposome containing latanoprost. Lipolat is an extended release drug delivery solution that is a ground breaking development in nanomedicine for ophthalmology. Liposomal latanoprost has completed a pilot Phase IIa trial in the US for glaucoma indication.

• BTQ-1902: Betaliq, Inc.

BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta blocker. Beta blockers are one of the most commonly prescribed classes of medicines to treat glaucoma. Beta blockers reduce Intraocular Pressure (IOP) by blockade of sympathetic nerve endings in the ciliary epithelium causing a fall in aqueous humour production. Beta blockers are often prescribed in combination with other glaucoma medications. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Open-Angle Glaucoma.

• ST266: Noveome Biotherapeutics

ST266 is a non-cellular biologic drug candidate, currently considered “investigational,” since it is not yet approved by the U.S. Food and Drug Administration (FDA). The clinical trials are designed to examine and confirm that ST266 is safe and effective in humans with the goal of bringing this unique product to potentially millions of patients who suffer from complex diseases and conditions in ophthalmology, neurology, dermatology—and beyond. ST266 is made by the proprietary method of culturing amnion epithelial cells that are harvested from donated full-term placentas normally discarded after birth. It contains hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. These various proteins and factors are delivered in physiologic concentrations that have been shown, in preclinical and clinical studies to date, to be well-tolerated with demonstrated biologic activity. In preclinical studies, ST266 has been shown to be neuroprotective and to resuscitate damaged and diseased retinal ganglion cells, offering the possibility of a novel treatment for glaucoma. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Glaucoma.

Further product details are provided in the report……..

Glaucoma Disease: Therapeutic Assessment

This segment of the report provides insights about the different Glaucoma Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Glaucoma Disease

There are approx. 50+ key companies which are developing the therapies for Glaucoma Disease. The companies which have their Glaucoma Disease drug candidates in the most advanced stage, i.e. phase III include, Nicox Ophthalmics.

• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Glaucoma Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glaucoma Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glaucoma Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glaucoma Disease drugs.

Glaucoma Disease Report Insights

• Glaucoma Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glaucoma Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Glaucoma Disease drugs?
• How many Glaucoma Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glaucoma Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glaucoma Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glaucoma Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Santen Pharmaceuticals
• Visiox Pharma
• Nicox Ophthalmics
• pH Pharma
• Omikron Italia
• Tarsier Pharma
• TearClear
• Laboratoires Thea
• EMS
• Peregrine Ophthalmic
• Betaliq, Inc.
• Ocuphire Pharma, Inc.
• HK inno.N
• VivaVision Biotech
• Qlaris Bio

Key Products

• DE-130A
• PDP-716
• NCX 470
• DE-126
• PHP-201
• Citicoline
• TRS01
• TC-002
• T4032
• Bremen
• POLAT 001
• BTQ-1902
• Nyxol
• IN-A010
• VVN539